Cord Blood News 10.43 November 1, 2018 | |
| |
TOP STORYIntegrated Stress Response Activity Marks Stem Cells in Normal Hematopoiesis and Leukemia Scientists showed that the integrated stress response (ISR) was uniquely active in hematopoietic stem cells (HSCs) and facilitated their persistence. Activating transcription factor 4 mediated the ISR and was highly expressed in HSCs due to scarcity of the eIF2 translation initiation complex. [Cell Rep] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers showed that interleukin-1β (IL-1β) induced CXC chemokine receptor 3 (CXCR3) expression on MSCs. Following pretreatment with protein synthesis inhibitor cycloheximide, they found that IL-1β induced CXCR3 on the surface of MSCs via the protein synthesis pathway. [Stem Cell Res Ther] Full Article Nuclear Nox4 Interaction with Prelamin A Is Associated with Nuclear Redox Control of Stem Cell Aging The authors investigated the aging process occurring during in vitro expansion of stem cells, obtained from amniotic fluids at similar gestational age. [Aging (Albany NY)] Full Article Researchers found that without Fms-related tyrosine kinase 3 ligand (hFlt3L) there were significantly increased types of human immune cells in NSG-huCD34 compared with NSG-huPBL mice but the frequency of human dendritic cells (DCs) remained low. Transient treatment with recombinant hFlt3L expanded human conventional CD1c+ and CD141+ DCs as well as plasmacytoid DCs in humanized NSG-huCD34 mice. [J Neuroimmune Pharmacol] Abstract | Graphical Abstract miR-9 Controls Chemotactic Activity of Cord Blood CD34+ Cells by Repressing CXCR4 Expression Since C-X-C chemokine receptor type 4 (CXCR4) is a specific receptor for the stromal cell derived factor-1 (SDF-1) chemotactic factor, scientists investigated whether sense miR-9 and antisense miR-9 influenced CXCR4-mediated chemotactic mobility of primary cord blood CD34+ cells and TF-1 cells. [Int J Stem Cells] Abstract Investigators describe the development of a 3D co-culture system of human umbilical cord blood-derived CD34+ cells and bone marrow MSC spheroids in a microwell-based platform that allows to attain large numbers of spheroids with uniform sizes. [Methods Mol Biol] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSAllogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukemia Acute myelogenous leukemia in the elderly is complex and has a poor prognosis, often characterized by higher risk cytogenetic and molecular features compared to that in younger patients. [Curr Treat Options Oncol] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSKadmon Initiates Pivotal Phase II Trial of KD025 in Chronic Graft-versus-Host Disease Kadmon Holdings, Inc. announced that the first patient has been dosed in a pivotal clinical trial of KD025 in chronic graft-versus-host (cGVHD) disease. The study will evaluate the efficacy and safety of KD025, Kadmon’s ROCK2 inhibitor, in adults with cGVHD who have received at least two prior lines of systemic therapy. [Kadmon Holdings, Inc.] Press Release Former Patient Donates $10 Million to Further Blood Cancer Research at UNC Lineberger A former patient of the North Carolina Cancer Hospital and a two-time alumnus of the University of North Carolina at Chapel Hill is showing his gratitude to the center that helped him heal. A $10 million gift will create a new fund supporting ground-breaking research in blood cancer at UNC Lineberger Comprehensive Cancer Center, including lymphoma, leukemia and myeloma research. [University of North Carolina at Chapel Hill] Press Release | |
| |
POLICY NEWSWhat Will a New California Law Mean for Biotech? Hundreds More Women in the Boardroom In the next few years, publicly traded life sciences companies headquartered in California could collectively need to add hundreds of women to their boards in order to comply with a new state gender-parity law. That’s going to mean finding women to fill 126 board seats in the sector by the end of 2019. [STAT News] Editorial Australia Plans ‘National-Interest’ Test for Research Grants Australia’s government is set to introduce a ‘national-interest test’ for research projects seeking grant funding from next year. The policy will require that researchers outline how their project will advance the country’s interests, said education minister Dan Tehan in a statement. [Nature News] Editorial Research Is Often Unpaid in Sub-Saharan Africa Unpaid research stints are the norm for scientists in sub-Saharan Africa, according to an online survey of 412 academics that spanned six countries. Eighty-five per cent of respondents report having had research positions with no pay. Of those, 33% had spent between one and five years doing research for free, and 4% had spent more than five years doing so. [Nature News] Editorial
| |
EVENTSNEW 15th Annual Stem Cell Symposium: Stem Cells B2B – Bench to Bedside Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Faculty Position – GVHD or Immunotherapy (Medical College of Wisconsin) NEW Senior Research Scientist – Flow Cytometry (MD Anderson Cancer Center) Research Scientist – Hematological Malignancies (MD Anderson Cancer Center) Research Fellow – Stem Cell Biology & Engineering (New York Blood Center) Postdoctoral Fellow – Blood Development & Disease (University of Washington) Senior Research Assistant – Stem Cell Transplantation (MD Anderson Cancer Center) Postdoctoral Associate – Hematopoiesis and Leukemia (The Jackson Laboratory) Postdoctoral Fellowship – Translational Leukemia (Lund University) Postdoctoral Fellow – Myelodysplasia and Acute Myeloid Leukemia (UNSW) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|